ReviewCardiovascular research2023
Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: implications for future interventions.
Review in Cardiovascular research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed, 4 syntheses or guidelines pooled it, 126 citations in OpenAlex.
- Comparative effectiveness of pharmacotherapy for heart failure with preserved ejection fraction: A systematic review and network meta-analysis.Diabetes, obesity & metabolism · 2026Pooled it
- Heart Failure with Preserved Ejection Fraction and Diastolic Dysfunction in Patients with Chronic Obstructive Pulmonary Disease: a Systematic Review.Current heart failure reports · 2026Pooled it
- Pooled it
- Prognostic value of epicardial adipose tissue in heart failure: a systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2025Pooled it
- A First-in-Human Study of Ulacamten, a Novel Cardiac Myosin Inhibitor for HFpEF.Clinical pharmacokinetics · 2026Trial
- Effects of metabolic syndrome on cardiovascular outcomes in non-obese heart failure patients.ESC heart failure · 2026Trial
- The Relationship Between the Systemic Immune Inflammatory Index and Atrial Fibrillation in Heart Failure with Preserved Ejection Fraction.The Eurasian journal of medicine · 2026Article
- Inflammatory and Genetic Determinants of Functional Status in HFpEF: The Role of Circulating IL-6 andBiomedicines · 2026Article
- A sex-specific perspective on coronary microvascular dysfunction in HFpEF: from vascular to myocardial disease.Heart failure reviews · 2026Review
- Non-HDL Cholesterol as a Practical Gatekeeper for Adolescent Dyslipidemia Screening: Implications for Nutrition and Public Health.Nutrients · 2026Article
- Association of routine inflammatory biomarkers and derived indices with heart failure progression in preserved ejection fraction.BMC cardiovascular disorders · 2026Article
- Relative Contributions of Functional Capacity and Inflammatory Activity to Quality of Life in Heart Failure with Preserved Ejection Fraction.Biomedicines · 2026Article
- Predictors of 1-Year Mortality Among Patients With Heart Failure With Preserved Ejection Fraction.JACC. Advances · 2026Article
- Mitochondrial dysfunction drives ZBP1-mediated PANoptosis to increase the susceptibility of heart failure with preserved ejection fraction-associated atrial fibrillation.Journal of advanced research · 2026Article
- D-dimer levels and outcomes in heart failure with mildly reduced ejection fraction.International journal of cardiology. Heart & vasculature · 2026Article
- Inflammation, metabolism, and aging in heart failure with preserved ejection fraction: Mechanisms and treatment perspectives.Journal of translational internal medicine · 2026Article
- Relationship between quantitative CT and cardiac function in patients with severe COPD exacerbations (ECOPD).BMJ open respiratory research · 2026Article
- Natural language processing of biomedical text to map and prioritize protein-disease associations in HFpEF.Computers in biology and medicine · 2026Article
- Galectin-1 Is a Marker but Not a Mediator of Heart Failure With Preserved Ejection Fraction.Hypertension (Dallas, Tex. : 1979) · 2026Article
- Benefits of sacubitril/valsartan alone and in combination with dapagliflozin in a preclinical female model of cardiometabolic and age-related cardiac dysfunction.Cardiovascular diabetology · 2026Article
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 3 countries.
Funding
Abstract
Many patients with symptoms and signs of heart failure have a left ventricular ejection fraction ≥50%, termed heart failure with preserved ejection fraction (HFpEF). HFpEF is a heterogeneous syndrome mainly affecting older people who have many other cardiac and non-cardiac conditions that often cast doubt on the origin of symptoms, such as breathlessness, or signs, such as peripheral oedema, rendering them neither sensitive nor specific to the diagnosis of HFpEF. Currently, management of HFpEF is mainly directed at controlling symptoms and treating comorbid conditions such as hypertension, atrial fibrillation, anaemia, and coronary artery disease. HFpEF is also characterized by a persistent increase in inflammatory biomarkers. Inflammation may be a key driver of the development and progression of HFpEF and many of its associated comorbidities. Detailed characterization of specific inflammatory pathways may provide insights into the pathophysiology of HFpEF and guide its future management. There is growing interest in novel therapies specifically designed to target deregulated inflammation in many therapeutic areas, including cardiovascular disease. However, large-scale clinical trials investigating the effectiveness of anti-inflammatory treatments in HFpEF are still lacking. In this manuscript, we review the role of inflammation in HFpEF and the possible implications for future trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.